Avanos clarifies Q2 2023 results beat consensus after third-party error

AVANOS MEDICAL, INC.

Third party incorrectly reported Avanos missed consensus; total sales including discontinued RH business were $199.8M.
Adjusted diluted EPS including discontinued ops was $0.37, ahead of consensus.
Continuing operations: net sales $169.4M, diluted loss per share $0.09, adjusted EPS $0.24.
RH business operating results reported as discontinued operations due to planned divestiture.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.